CEL-SCI Corporation (CVM) |
|
2.78 0.06 (2.21%)
|
02-07 16:00 |
|
Open: |
2.68 |
Pre. Close: |
2.72 |
|
High:
|
2.7873 |
Low:
|
2.65 |
|
Volume:
|
69,588 |
Market Cap:
|
121(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:27:32 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 3.63 One year: 4.24 |
| Support: |
Support1: 2.67 Support2: 2.4 |
| Resistance: |
Resistance1: 3.1 Resistance2: 3.63 |
| Pivot: |
2.73  |
| Moving Average: |
MA(5): 2.7 MA(20): 2.74
MA(100): 2.95 MA(250): 3.58 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 36.1 %D(3): 28.3 |
| RSI: |
RSI(14): 55.9 |
| 52-week: |
High: 6.13 Low: 1.87 |
| Average Vol(K): |
3-Month: 175 (K) 10-Days: 69 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CVM ] has closed below upper band by 37.3%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.79 - 2.8 |
2.8 - 2.81 |
|
Low:
|
2.62 - 2.63 |
2.63 - 2.65 |
|
Close:
|
2.76 - 2.78 |
2.78 - 2.8 |
|
Company Description |
|
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. |
Headline News |
Wed, 08 Feb 2023
Americanas' $4B Accounting Scandal Puts More Scrutiny on PwC's ... - Insurance Journal
Tue, 07 Feb 2023
Light : Notice to the market - Clarification on CVM/B3 inquiries - Marketscreener.com
Tue, 07 Feb 2023
LMU-CVM exhibits at USPC convention - Claiborne Progress - Claiborne Progress
Mon, 06 Feb 2023
Deer may be reservoir for SARS-Cov-2 variants, study suggests - VeterinaryPracticeNews.com
Thu, 02 Feb 2023
Sigma CVM Romania Announces National Distribution Partnership ... - Business Review
Sun, 29 Jan 2023
Norwegian Marine Equipment Supplier Teco 2030 Chooses CVM ... - Hydrogen Central
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
43 (M) |
| Shares Float |
41 (M) |
|
% Held by Insiders
|
3.8 (%) |
|
% Held by Institutions
|
38.3 (%) |
|
Shares Short
|
7,910 (K) |
|
Shares Short P.Month
|
8,660 (K) |
Stock Financials |
|
EPS
|
-0.94 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.42 |
|
EPS Est Next Year
|
-0.29 |
|
Book Value (p.s.)
|
1.3 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-38.9 |
|
Return on Equity (ttm)
|
-96.3 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.54 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-2.99 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.12 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-6.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-06-14 |
|
Ex-Dividend Date
|
1996-08-27 |
|
Your Ad Here
|
|
